Scynexis, Inc. · NASDAQ:SCYX
Scynexis — Investor Presentation (March 2026)
20 slides from Scynexis's investor presentation, Mar 31, 2026
Slide 1: Advancing innovative solutions for severe rare diseases
Exhibit 99.1 Advancing innovative solutions for severe rare diseases Corporate Deck March 2026
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc. (the “Company”) solely for informational purposes. This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of applicable securities laws and ar
Slide 3: Agenda and Speakers
AGENDA and SPEAKERS David Angulo, M.D. President and Chief Executive Officer • Corporate Update and Strategic Asset Acquisition Jeremy Duffield, MD, PhD • ADPKD & SCY-770: Disease Landscape Consultant - Expertise in ADPKD and Scientific Rationale Rossana Ferrara-Pontoriero, PhD VP, Business Developm
Slide 4: SCYNEXIS: Innovation-Driven Focus on Severe Rare Diseases
SCYNEXIS: Innovation-Driven Focus on Severe Rare Diseases Optionality & Upside from Strategic Asset Acquisition Successful $40M Financing Antifungal Assets SCY-247 SCY-770 for Autosomal Dominant Raised $40M in PIPE financing, • Oral Phase 1 completed Polycystic Kidney Disease extending our cash runw
Slide 5: Clinical Stage Asset Acquisition in ADPKD
Clinical Stage Asset Acquisition in ADPKD Area of high unmet need and significant commercial opportunity • Jynarque (tolvaptan), the only approved treatment, reached ~$1.5B US sales in 2024 despite significant safety and tolerability limitations SCY-770 Significant interest from pharma and investor
Slide 6: SCY-770: Well-Characterized, Phase-Ready AMPK Activator
SCY-770: Well-Characterized, Phase 2 - Ready AMPK Activator • Solid scientific support for AMPK role in ADPKD Novel Mechanism: Direct • Compelling pre-clinical pharmacology package supportive of efficacy AMPK Activator • Evidence of target engagement and PK/PD correlation in a Phase 2a study (NAFLD)
Slide 7: ADPKD & SCY-770: Disease Landscape and Scientific Rationale
ADPKD & SCY-770: Disease Landscape and Scientific Rationale 7
Slide 8: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) 1 U.S. Prevalence: ~140,000 patients ADPKD is a genetic disease caused by mutations of the PKD1 or PKD2 genes which encode polycystin complex 1 (PC1) or polycystin complex 2 (PC2) proteins, critical for normal tubular epithelial cell function Pati
Slide 9: AMPK is Involved in Multiple Pathophysiological Aspects of ADPKD
AMPK is Involved in Multiple Pathophysiological Aspects of ADPKD AMPK is a metabolic regulator of cellular energy homeostasis that increases glucose and fatty acid uptake and oxidation when cellular energy is low. It can be activated by several physiological and pharmacological mechanisms • There ar
Slide 10: SCY-770 Demonstrated Robust in vivo Effects in ADPKD Mice
SCY-770 – Demonstrated Robust in vivo Effects in ADPKD Mice Improved survival and renal function Tamoxifen-inducible kidney epithelium–specific Pkd1 deletion (Ksp-TamCre x Pkd1Lox), mice sacrificed when blood urea level was ≥ 20mM (ESRD) and study was terminated when 50% of control mice reached this
Slide 11: SCY-770 Development Plan
SCY-770 Development Plan SCYNEXIS
Slide 12: SCY-770 Illustrative Path Forward
SCY-770 Illustrative Path Forward 1 Potential accelerated approval based on surrogate endpoint (htTKV) Phase 1* Phase 2 POC EoP2 Phase 3 16-week htTKV FDA inflection point 12-months 24-month htTKV eGFR NDA sNDA htTKV = measures the kidney volume changes via MRI eGFR = measures the kidney function ch
Slide 13: SCY-770 Planned Phase 2 Study Design in ADPKD
SCY-770 Planned Phase 2 Study Design in ADPKD Objective: provide clinical evidence of SCY-770 magnitude of effect in ADPKD patients Cohorts Anticipated timelines: Analysis 2026 Q4 Study Initiation 2027 Randomized Double-Blind Q2/Q3 Enrollment completion Open Label H2 POC 16-week htTKV data 2028 SCY-
Slide 14: ADPKD: Market Landscape & Therapeutic Opportunity
ADPKD: Market Landscape & Therapeutic Opportunity 14
Slide 15: ADPKD is an Orphan Indication with Significant Clinical and Economic Burden
ADPKD is an Orphan Indication Associated with Significant Clinical and Economic Burden 1 2 U.S. prevalence of ~140,000 patients with ~6,000 new cases diagnosed / year 1,2 1 Clinical Burden Economic Burden Kidney Impact ~$7.3B-$9.8B in incremental costs equivalent to ~$52k-$68k per individual with AD
Slide 16: Jynarque, the Only Approved Product for ADPKD, Reached Blockbuster Status
Jynarque, the Only Approved Product for ADPKD Reached Blockbuster Status Despite Limited Uptake 1 In 2024, Otsuka reported ~$1.5B despite limited penetration (<10%*) of total diagnosed population 2 Annual Jynarque U.S. Sales ($M) • Black box warning due to the potential for fatal $1,528 3 liver inju
Slide 17: Financial Update & Outlook
Financial Update & Outlook 17
Slide 18: Financial Outlook
Financial Outlook SCYNEXIS is well-capitalized to support execution of development plans • Cash runway into mid-2029 • ~$56M in cash, cash equivalents and investments as of 12/31/2025 • ~$40M of gross proceeds from recent PIPE • No debt Potential to receive up to $146M in Pursuing non-dilutive finan
Slide 19: SCYNEXIS Pipeline
SCYNEXIS Pipeline Lead program focused on ADPKD Preclinical Phase 1 Phase 2 Phase 3 Status • Phase 1 confirmatory study planned in Q2 2026 ADPKD Oral • Phase 2 POC initial readout expected in H2 2027 SCY-770 ALD and other Oral • Phase 2 ready relevant diseases • Completed Phase 1 Oral Treatment of I
Slide 20: SCYNEXIS: Anchored by Strong Fundamentals
SCYNEXIS: Anchored by Strong Fundamentals Combining key elements to create value for all stakeholders Committed to Innovative Science: Clear Go-Forward Strategy Achievable Targeting Severe, Rare Conditions with Existing Resources • SCY-770: Clinical stage, novel highly selective • Generate early eff